JAK2 and acute lymphoblastic leukemia: In DS-ALL, its co-occurrence with JAK2 R683, CRLF2 rearrangement, EP300 loss-of-function, and iAMP21 suggests synergistic pathway of deregulation and likely accounts for the aggressive molecular phenotype observed in our patient.